Leyre Bento, Antonio Gutiérrez, Carmen Martinez, María Consejo Ortí Verdet, Marina Sorribes Portella, Ana Carolina Caballero Gonzalez, Marta Peña, Ariadna Pérez, Ana Jiménez-Ubieto, Lucía Medina, Mariana Beatriz Bastos Oreiro, Paula Fernández Caldas-González, Maria Belen Navarro, Isabel Salcedo, Pau Abrisqueta, Ignacio Español, Javier Cornago Navascués, Fernando Martin-Moro, Lucía García Tomás, Pilar Gómez-Prieto, María Rosario Varela, María Puente, Joud Zanabili, Teresa Zudaire, Izaskun Zeberio, Raquel Del Campo, Leslie González Pinedo, Pedro Antonio Gonzalez-Sierra, Cristina Blázquez-Goñi, Jordina Rovira, Marta Sitges, Mireia Franch-Sarto, Almudena Cabero Martínez, Alberto Mussetti, Juan Montoro, Antonia Sampol, Anna Sureda, Dolores Caballero-Barrigon, Alejandro Martin Martin Garcia-Sancho
{"title":"自体干细胞移植治疗复发/难治性大B细胞淋巴瘤：多中心GETH-TC/GELTAMO研究","authors":"Leyre Bento, Antonio Gutiérrez, Carmen Martinez, María Consejo Ortí Verdet, Marina Sorribes Portella, Ana Carolina Caballero Gonzalez, Marta Peña, Ariadna Pérez, Ana Jiménez-Ubieto, Lucía Medina, Mariana Beatriz Bastos Oreiro, Paula Fernández Caldas-González, Maria Belen Navarro, Isabel Salcedo, Pau Abrisqueta, Ignacio Español, Javier Cornago Navascués, Fernando Martin-Moro, Lucía García Tomás, Pilar Gómez-Prieto, María Rosario Varela, María Puente, Joud Zanabili, Teresa Zudaire, Izaskun Zeberio, Raquel Del Campo, Leslie González Pinedo, Pedro Antonio Gonzalez-Sierra, Cristina Blázquez-Goñi, Jordina Rovira, Marta Sitges, Mireia Franch-Sarto, Almudena Cabero Martínez, Alberto Mussetti, Juan Montoro, Antonia Sampol, Anna Sureda, Dolores Caballero-Barrigon, Alejandro Martin Martin Garcia-Sancho","doi":"10.1182/bloodadvances.2024015415","DOIUrl":null,"url":null,"abstract":"<p><p>We performed a retrospective multicenter study including 791 patients with relapsed/refractory (R/R) large B cell lymphoma (LBCL) who underwent ASCT from 2010-2021. All the patients received rituximab and anthracycline-based frontline therapy. After a median follow-up of 74 months (95%CI 68-81) from infusion, 65% of the patients were alive and 84% of them free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% (95%CI 47-54) and 63% (95%CI 60-67), respectively. Non-relapse mortality (NRM) at 1 year was 9% (95%CI 7-11). Age >60 years at ASCT [HR 1.31 (95%CI 1.06-1.62), p=0.011], ASCT as ≥3rd line [HR 1.81 (95%CI 1.42-2.31), p<0.001] and partial response (PR) versus complete response (CR) at ASCT [HR 1.46 (95%CI 1.18-1.81), p<0.001] were the independent variables influencing PFS. Age >60 years at ASCT [HR 1.62 (95%CI 1.24-2.12), p<0.001], time period before first of November 2012 [HR 1.40 (95%CI 1.07-1.83), p=0.014], ASCT as ≥3rd line [HR 1.77 (95%CI 1.32-2.37), p<0.001], PR versus CR [HR 1.58 (95%CI 1.22-2.05), p<0.001] and stable disease (SD) versus CR pre-ASCT [HR 3.41 (95%CI 1.81-6.45), p<0.001] were the variables associated with worse OS. Refractory or early relapse did not significantly influence survival (6y-PFS and OS in patients with refractory, early and late relapse was 54% and 64%; 46% and 62% and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Autologous Stem Cell Transplantation for Relapsed/Refractory Large B Cell Lymphoma: Multicenter GETH-TC/GELTAMO Study.\",\"authors\":\"Leyre Bento, Antonio Gutiérrez, Carmen Martinez, María Consejo Ortí Verdet, Marina Sorribes Portella, Ana Carolina Caballero Gonzalez, Marta Peña, Ariadna Pérez, Ana Jiménez-Ubieto, Lucía Medina, Mariana Beatriz Bastos Oreiro, Paula Fernández Caldas-González, Maria Belen Navarro, Isabel Salcedo, Pau Abrisqueta, Ignacio Español, Javier Cornago Navascués, Fernando Martin-Moro, Lucía García Tomás, Pilar Gómez-Prieto, María Rosario Varela, María Puente, Joud Zanabili, Teresa Zudaire, Izaskun Zeberio, Raquel Del Campo, Leslie González Pinedo, Pedro Antonio Gonzalez-Sierra, Cristina Blázquez-Goñi, Jordina Rovira, Marta Sitges, Mireia Franch-Sarto, Almudena Cabero Martínez, Alberto Mussetti, Juan Montoro, Antonia Sampol, Anna Sureda, Dolores Caballero-Barrigon, Alejandro Martin Martin Garcia-Sancho\",\"doi\":\"10.1182/bloodadvances.2024015415\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We performed a retrospective multicenter study including 791 patients with relapsed/refractory (R/R) large B cell lymphoma (LBCL) who underwent ASCT from 2010-2021. All the patients received rituximab and anthracycline-based frontline therapy. After a median follow-up of 74 months (95%CI 68-81) from infusion, 65% of the patients were alive and 84% of them free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% (95%CI 47-54) and 63% (95%CI 60-67), respectively. Non-relapse mortality (NRM) at 1 year was 9% (95%CI 7-11). Age >60 years at ASCT [HR 1.31 (95%CI 1.06-1.62), p=0.011], ASCT as ≥3rd line [HR 1.81 (95%CI 1.42-2.31), p<0.001] and partial response (PR) versus complete response (CR) at ASCT [HR 1.46 (95%CI 1.18-1.81), p<0.001] were the independent variables influencing PFS. Age >60 years at ASCT [HR 1.62 (95%CI 1.24-2.12), p<0.001], time period before first of November 2012 [HR 1.40 (95%CI 1.07-1.83), p=0.014], ASCT as ≥3rd line [HR 1.77 (95%CI 1.32-2.37), p<0.001], PR versus CR [HR 1.58 (95%CI 1.22-2.05), p<0.001] and stable disease (SD) versus CR pre-ASCT [HR 3.41 (95%CI 1.81-6.45), p<0.001] were the variables associated with worse OS. Refractory or early relapse did not significantly influence survival (6y-PFS and OS in patients with refractory, early and late relapse was 54% and 64%; 46% and 62% and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.</p>\",\"PeriodicalId\":9228,\"journal\":{\"name\":\"Blood advances\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2025-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood advances\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1182/bloodadvances.2024015415\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024015415","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Autologous Stem Cell Transplantation for Relapsed/Refractory Large B Cell Lymphoma: Multicenter GETH-TC/GELTAMO Study.
We performed a retrospective multicenter study including 791 patients with relapsed/refractory (R/R) large B cell lymphoma (LBCL) who underwent ASCT from 2010-2021. All the patients received rituximab and anthracycline-based frontline therapy. After a median follow-up of 74 months (95%CI 68-81) from infusion, 65% of the patients were alive and 84% of them free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% (95%CI 47-54) and 63% (95%CI 60-67), respectively. Non-relapse mortality (NRM) at 1 year was 9% (95%CI 7-11). Age >60 years at ASCT [HR 1.31 (95%CI 1.06-1.62), p=0.011], ASCT as ≥3rd line [HR 1.81 (95%CI 1.42-2.31), p<0.001] and partial response (PR) versus complete response (CR) at ASCT [HR 1.46 (95%CI 1.18-1.81), p<0.001] were the independent variables influencing PFS. Age >60 years at ASCT [HR 1.62 (95%CI 1.24-2.12), p<0.001], time period before first of November 2012 [HR 1.40 (95%CI 1.07-1.83), p=0.014], ASCT as ≥3rd line [HR 1.77 (95%CI 1.32-2.37), p<0.001], PR versus CR [HR 1.58 (95%CI 1.22-2.05), p<0.001] and stable disease (SD) versus CR pre-ASCT [HR 3.41 (95%CI 1.81-6.45), p<0.001] were the variables associated with worse OS. Refractory or early relapse did not significantly influence survival (6y-PFS and OS in patients with refractory, early and late relapse was 54% and 64%; 46% and 62% and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.
期刊介绍：
Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016.
Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
